JP2025508337A - 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 - Google Patents

疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 Download PDF

Info

Publication number
JP2025508337A
JP2025508337A JP2024544912A JP2024544912A JP2025508337A JP 2025508337 A JP2025508337 A JP 2025508337A JP 2024544912 A JP2024544912 A JP 2024544912A JP 2024544912 A JP2024544912 A JP 2024544912A JP 2025508337 A JP2025508337 A JP 2025508337A
Authority
JP
Japan
Prior art keywords
peptide
exon
antisense oligonucleotide
pmo
conjugated antisense
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024544912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508337A5 (https=
JPWO2023141710A5 (https=
Inventor
トシフミ ヨコタ
リカ ヨコタ－マルヤマ
ホン エム． モールトン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Alberta
Oregon State University
Original Assignee
University of Alberta
Oregon State University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Alberta, Oregon State University filed Critical University of Alberta
Publication of JP2025508337A publication Critical patent/JP2025508337A/ja
Publication of JP2025508337A5 publication Critical patent/JP2025508337A5/ja
Publication of JPWO2023141710A5 publication Critical patent/JPWO2023141710A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3513—Protein; Peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
JP2024544912A 2022-01-27 2023-01-26 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤 Pending JP2025508337A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263303577P 2022-01-27 2022-01-27
US63/303,577 2022-01-27
PCT/CA2023/050096 WO2023141710A1 (en) 2022-01-27 2023-01-26 Pre-mrna slice modulating peptide-conjugated antisense therapeutics for the treatment of diseases

Publications (3)

Publication Number Publication Date
JP2025508337A true JP2025508337A (ja) 2025-03-26
JP2025508337A5 JP2025508337A5 (https=) 2026-02-03
JPWO2023141710A5 JPWO2023141710A5 (https=) 2026-02-03

Family

ID=87469898

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024544912A Pending JP2025508337A (ja) 2022-01-27 2023-01-26 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤

Country Status (6)

Country Link
US (1) US20250114464A1 (https=)
EP (1) EP4469576A4 (https=)
JP (1) JP2025508337A (https=)
CN (1) CN119137274A (https=)
CA (1) CA3243078A1 (https=)
WO (1) WO2023141710A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
EP3829595A4 (en) 2018-08-02 2022-08-24 Dyne Therapeutics, Inc. MUSCLE-DIRECTED COMPLEXES AND USES THEREOF IN THE TREATMENT OF DYSTROPHINOPATHIES
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US20220193250A1 (en) 2018-08-02 2022-06-23 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US12497615B2 (en) 2019-04-25 2025-12-16 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9161948B2 (en) * 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9801948B2 (en) * 2011-09-21 2017-10-31 Yale University Antimicrobial compositions and methods of use thereof
US20220288218A1 (en) * 2019-07-09 2022-09-15 The Governors Of The University Of Alberta Exons 45-55 skipping using mutation-tailored cocktails of antisense morpholinos in the dmd gene
US20230048338A1 (en) * 2019-12-20 2023-02-16 PYC Therapeutics Limited Novel cellular delivery methods

Also Published As

Publication number Publication date
US20250114464A1 (en) 2025-04-10
EP4469576A4 (en) 2026-04-15
EP4469576A1 (en) 2024-12-04
WO2023141710A1 (en) 2023-08-03
CA3243078A1 (en) 2023-08-03
CN119137274A (zh) 2024-12-13

Similar Documents

Publication Publication Date Title
JP2025508337A (ja) 疾患治療用のプレｍＲＮＡスライス調節ペプチド共役アンチセンス治療剤
JP7742205B2 (ja) ヒトジストロフィンプレｍＲＮＡのエクソン５１に結合するアンチセンスオリゴヌクレオチド
US20210145852A1 (en) Combination Therapies for Treating Muscular Dystrophy
Hua et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
US11236329B2 (en) Compound and method for treating myotonic dystrophy
US9506058B2 (en) Compositions for treating muscular dystrophy
US9302014B2 (en) Cell-penetrating peptides having a central hydrophobic domain
EP3687547A1 (en) Combination therapies for treating muscular dystrophy
ES2699827T3 (es) Composiciones y métodos para la modulación de corte y empalme de SMN2 en un sujeto
EP2892617B1 (en) Antisense polynucleotides to induce exon skipping and methods of treating dystrophies
US10689653B2 (en) Compositions and methods for modulating dysferlin expression
US20200254002A1 (en) Combination therapies for treating muscular dystrophy
US20120309684A1 (en) Conjugates for delivery of biologically active compounds
Aslesh et al. DG9-conjugated morpholino rescues phenotype in SMA mice by reaching the CNS via a subcutaneous administration
US20140243388A1 (en) Antisense oligonucleotides that target a cryptic splice site in ush1c as a therapeutic for usher syndrome
Aslesh Development of antisense therapy for the treatment of Spinal Muscular Atrophy and Investigating the role of Aquaporins in skeletal muscle function
HK40108458A (zh) 结合至人类肌养蛋白前体mrna的外显子51的反义寡核苷酸
HK40030260B (zh) 结合至人类肌养蛋白前体mrna的外显子51的反义寡核苷酸
HK40030260A (en) Antisense oligonucleotides that bind to exon 51 of human dystrophin pre-mrna

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260126

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260126